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SUMMARY 
1 
SUMMARY 
Metamizole is a non-opioid analgesic, antipyretic, and spasmolytic prodrug, which is widely 
prescribed in certain countries due to its good efficacy and low gastrointestinal toxicity. Despite 
the favorable safety profile overall, metamizole has been banned in several countries due to 
reports of metamizole-associated neutropenia, a severe and potentially fatal decrease of 
circulating neutrophil granulocytes. In Switzerland and Germany, metamizole use has increased 
over the last fifteen years even though it has been restricted to narrow indications. 
The aim of this PhD project was to elucidate the underlying toxicological mechanisms of 
metamizole-associated neutropenia. The gained knowledge could lead to a better understanding 
of the cellular mechanisms of metamizole-associated neutropenia and improve the safety of 
metamizole treatment. Hence, this thesis is composed of toxicological in vitro investigations of 
direct metamizole metabolite toxicity on neutrophils and neutrophil progenitor cells as well as of 
clinical investigations composed of an observational case-control study. 
For the in vitro part of this thesis, I investigated the cytotoxicity of metamizole and its main 
metabolites on the promyelocytic cell line HL60 in comparison with mature neutrophils. To form 
potentially cytotoxic secondary metabolites, I combined the metamizole metabolites with 
components of the neutrophil antioxidative system. Furthermore, I assessed potential formation 
of cytotoxic metabolites after combination of metamizole metabolites with various iron 
compounds found in neutrophils and blood. None of the tested metamizole metabolites was 
toxic in any cell line. The main metamizole metabolite N-methyl-4-aminoantipyrine (MAA) even 
reduced cytotoxicity of the myeloperoxidase substrate hydrogen peroxide at low concentrations 
(< 50 μM), but increased cytotoxicity at a concentration of 100 μM hydrogen peroxide. In 
contrast, neutrophil granulocytes were resistant to any tested hydrogen peroxide concentration 
and MAA. Furthermore, MAA did not increase the toxicity of the iron compounds lactoferrin, 
hemoglobin or methemoglobin in HL60 cells. However, the hemoglobin degradation product 
hemin was toxic on HL60 cells and cytotoxicity was increased by MAA. The radical scavengers 
N-acetylcysteine and glutathione as well as the iron chelator ethylenediaminetetraacetic acid 
(EDTA) were able to reduce the toxicity of hemin and MAA-hemin. The interaction between the 
trivalent iron ion of hemin and MAA was displayed in the absorption spectrum of hemin. The 
spectrum changed concentration-dependently after addition of MAA, suggesting an interaction 
between hemin iron and MAA. The corresponding NMR of the combination MAA and hemin 
revealed the formation of a stable MAA reaction product with a reaction pathway involving the 
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formation of an electrophilic intermediate. Hence, the main metamizole metabolite MAA 
increased the cytotoxicity of hemin by a reaction involving the formation of an electrophilic 
metabolite, which elicits apoptosis in promyelocytic HL60 cells but not in mature neutrophil 
granulocytes. These results suggest that the cellular antioxidative defense system and/or heme-
metabolizing capacity changes during neutrophil differentiation, rendering mature cells less 
susceptible to the reactive MAA intermediate. Thus, I assessed the toxicity of hemin and MAA 
on differentiating HL60 cells that were differentiated into mature neutrophils over 5 days. After 3 
days differentiation, the cell population was predominantly metamyelocytic and resistant against 
MAA-hemin, whereas hemin alone was still cytotoxic. At 5 days of differentiation, when the cell 
population consisted mainly of mature neutrophils, hemin was not toxic anymore. These results 
were compared with immature myeloid cells from umbilical cord blood, representing early 
neutrophil precursor cells, which were differentiated over 14 days into the neutrophil lineage. 
Similarly to promyelocytic HL60 cells, MAA-hemin was more toxic than hemin alone on 
immature myeloid cells from umbilical cord blood. However, no cytotoxicity was observed on 
freshly isolated human neutrophils. During differentiation of HL60 cells, the protein expression 
of enzymes responsible for hemin metabolism increased. Inhibition of the heme-metabolizing 
enzymes heme oxygenase-1 or cytochrome P450 reductase increased hemin and MAA-hemin 
toxicity in undifferentiated HL60 cells. In differentiated HL60 cells, only hemin was cytotoxic. 
Furthermore, protein expression of enzymes involved in defense against superoxide radicals and 
hydrogen peroxide degradation increased with HL60 cell differentiation. Accordingly, the cellular 
glutathione pool, which represents the non-enzymatic antioxidative defense system, increased in 
parallel with HL60 cell differentiation. Hence, the resistance of differentiated HL60 cells is 
associated with the development of heme metabolism and of the antioxidative defense system 
including the cellular glutathione pool. 
The observational case-control study aimed to identify possible risk factors for the development 
of neutropenia associated with metamizole use. Therefore, 48 patients with metamizole-
associated neutropenia treated at the University Hospitals Basel and Bern (2005-2017) were 
characterized and compared with 39 tolerant controls who took metamizole for at least 28 days 
perpetually without developing neutropenia. Neutropenia patients were subdivided into inpatient 
or outpatient cases who had developed neutropenia after metamizole treatment in the hospital or 
at home, respectively. Hence, outpatient cases were compared in more detail with tolerant control 
patients who had also received metamizole in an outpatient treatment setting. Due to the similar 
treatment circumstances, it was possible to analyze risk factors in a regression-based model. The 
main finding of this study was the increased frequency of acute infections among neutropenia 
patients before neutropenia diagnosis compared to tolerant control patients. There was no 
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association between the development of neutropenia after metamizole treatment and non-
myelotoxic and non-immunosuppressive co-medication (p=0.6627), history of drug allergy 
(p=0.1304), or preexisting auto-immune diseases (p=0.2313). Thus, acute infections may increase 
the risk to develop neutropenia during metamizole treatment. But since it cannot be distinguished 
for all case patients, whether this is a consequence of or a risk factor for neutropenia, further 
investigation is needed. 
In conclusion, the main metamizole metabolite MAA can form an electrophilic intermediate in 
presence of hemin and potentially also in presence of other highly oxidative compounds. Thus, 
weak antioxidative defense, low heme-metabolizing capacity, or increased generation of free 
heme or other highly oxidative compounds, as it might occur during infections, may render cells 
more susceptible to MAA toxicity and therefore facilitate neutropenia development. 
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ABBREVIATIONS 
AA 4-aminoantipyrine 
AAA N-acetyl-4-aminoantipyrine 
ADR Adverse drug reaction 
ATP Adenosine triphosphate 
COX Cyclooxygenase 
DNA Deoxyribonucleic acid 
EDTA Ethylenediaminetetraacetic acid 
FAA N-formyl-4-aminoantipyrine 
G-CSF Granulocyte-colony stimulating factor 
HIV Human immunodeficiency virus 
HLA Human leukocyte antigen 
IC50 Half maximal inhibitory concentration 
MAA N-methyl-4-aminoantipyrine 
MPO Myeloperoxidase 
NADPH Nicotinamide adenine dinucleotide phosphate 
NET Neutrophil extracellular trap 
NSAID Nonsteroidal anti-inflammatory drug 
ROS Reactive oxygen species 
SOD Superoxide dismutase 
STEAP Six transmembrane epithelial antigen of the prostate 
INTRODUCTION 
5 
1. INTRODUCTION 
1.1. Metamizole 
1.1.1. History and background 
Metamizole (dipyrone) was first synthesized by the German company Hoechst AG in 1920 and 
was available over-the-counter in many countries worldwide until the 1970s (Nikolova et al. 
2012). Due to several reports of cases with fatal agranulocytosis, metamizole was withdrawn from 
the market in certain countries (e.g. Australia 1965, Norway 1976, USA 1977, Denmark 1979) 
whereas its use has been restricted to second-line treatment and reclassified as prescription drug 
in other countries (e.g. Germany 1987, Spain 1989, Switzerland 1992) (UnitedNations 2005). To 
evaluate the actual risk of metamizole-associated neutropenia, several studies have been 
performed. The International Agranulocytosis and Aplastic Anemia Study (IAAAS), a 
population-based case-control study was conducted in the 1980s to assess the risk-benefit profile 
of various analgesics (IAAAS 1986). The study included agranulocytosis cases and controls from 
several European countries, resulting in an estimated excess risk for any exposure to metamizole 
in a one-week period of 1.1 per million. Strikingly, the incidences varied depending on the 
country, which was reflected in later studies investigating metamizole-associated neutropenia risk. 
This resulted in locally different incidence rates. In Sweden, metamizole had been banned in 1974 
due to agranulocytosis reports and was reintroduced to the market in 1995 based on the IAAA 
study. After several new agranulocytosis cases, metamizole has again been withdrawn from the 
Swedish market in 1999 (UnitedNations 2005). A local Swedish study reported an incidence rate 
of approximately 1:1500 prescriptions, which were based on eight community cases and over 
10’000 prescriptions in the period of 1995 to 1999 (Hedenmalm and Spigset 2002). In contrary, a 
Spanish study including several hematology units in the greater area of Barcelona, reported an 
incidence of 0.56 cases per million inhabitants and year (Ibáñez et al. 2005). These results are in 
line with a recent study from Switzerland, where an incidence of around 1 case per million 
person-days of use was found for metamizole use between 2006 and 2012 (Blaser et al. 2015). 
The apparent differences between the studies might derive from the different study designs and 
inclusion criteria used in these studies. Additionally, a genetic predisposition could account for 
the observed regional differences.  
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1.1.2. Properties 
Chemically, metamizole is a pyrazole consisting of an antipyrine substituted at C-4 by a 
methyl(sulfomethyl)amino group (EMBL-EBI 2018). Metamizole is a prodrug, which after 
application is immediately demethylated in the gut or mesenteric and portal circulation to its main 
metabolite N-methyl-4-aminoantipyrine (MAA). MAA is the main active metamizole derivative 
with a high oral bioavailability of >80% and elimination half-life of 3.3 hours (Documed 2017; 
Ergun et al. 2004). MAA can either be demethylated to the less active metabolite 4-
aminoantipyrine (AA) or formylated to the inactive metabolite N-formyl-4-aminoantipyrine 
(FAA) (Levy et al. 1995). Demethylation of MAA is catalyzed by a combination of CYP3A4, 2B6, 
2C8, and 2C9. Additionally, myeloperoxidase (MPO), which is contained in neutrophils, is able to 
demethylate MAA in presence of hydrogen peroxide. The demethylation capacity of neutrophils 
and MPO containing neutrophil precursor cells was found to be considerably larger than the 
hepatic capacity and sufficient to account for the entire demethylation of MAA in humans 
(Bachmann et al. 2018). The demethylation product AA can be further acetylated to the inactive 
metabolite N-acetyl-4-aminoantipyrine (AAA) (Geisslinger et al. 1996). All four metabolites are 
excreted predominantly in the urine (Zylber-Katz et al. 1992). Besides these four main 
metabolites, additional minor metabolites have been described and some metabolites are still 
unknown (Rogosch et al. 2012; Volz and Kellner 1980). 
1.1.3. Mechanism of action 
Metamizole is used in human and veterinary medicine due to its analgesic, antipyretic and 
spasmolytic effects (Blaser et al. 2015; Jasiecka et al. 2014; Sanchez et al. 2002). Although still 
under debate, it is likely that the mode of action includes several different mechanisms.  
1.1.3.1. Analgesic effect 
Metamizole has been shown to inhibit cyclooxygenase (COX) and thus decreases prostaglandin 
synthesis (Campos et al. 1999; Chandrasekharan et al. 2002; Hinz et al. 2007; Pierre et al. 2007). 
Whereas some studies showed equipotent inhibition of COX-1 and COX-2 by metamizole, 
others demonstrated lower IC50 values for COX-2 inhibition compared to COX-1 (Campos et al. 
1999; Hinz et al. 2007; Pierre et al. 2007). Additionally, COX-3 inhibition by metamizole has been 
shown to be more potent than COX-1 and COX-2 inhibition (Chandrasekharan et al. 2002). The 
underlying mechanism of COX inhibition has been investigated intensively. It has been suggested 
that the main metamizole metabolite MAA targets the initiation of the catalytic reaction of 
COX-1 and COX-2 by reducing the higher oxidation states of COX (Pierre et al. 2007). In 
addition, MAA and AA can form metabolites with the COX substrate arachidonic acid that were 
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tested positive for COX-1 and COX-2 inhibition and cannabis receptor binding (Rogosch et al. 
2012). The latter would lead to analgesic and spasmolytic effects through the endocannabinoid 
system. Various additional modes of action have been proposed, including interactions with 
glutamate-dependent transmission and a modulating effect of glutamate-induced hyperalgesia 
(Beirith et al. 1998; Siebel et al. 2004), potential release of noradrenaline and therefore interaction 
with the adrenergic system (Silva et al. 2015), and activation of ATP-sensitive potassium channels 
as well as large- and small-conductance calcium-activated potassium channels (Alves and Duarte 
2002; Ortiz et al. 2003).  
1.1.3.2. Spasmolytic effect 
The spasmolytic effect of metamizole is assumed to affect the vascular smooth muscles. 
Proposed mechanisms are metamizole affecting ATP sensitive potassium channels by 
angiotensinogen II inhibition resulting in vasodilatation (Valenzuela et al. 2005) or inhibition of 
intracellular calcium release by direct inhibition of phospholipase C or impairment of 
phospholipase C activation by G protein-coupled receptor (Gulmez et al. 2006). 
1.1.3.3. Antipyretic effect 
Metamizole exerts a strong antipyretic effect, whose mechanism is still not understood. It has 
been assumed that metamizole acts centrally on the hypothalamic heat-regulating center 
(Nikolova et al. 2012). Furthermore, COX inhibition and thus decreasing prostaglandin E2 
synthesis in the CNS has been proposed as mechanism of the antipyretic effect. Recent studies 
showed inhibition of prostaglandin E2 synthesis in the hypothalamus by metamizole or its 
metabolites MAA and AA in parallel with reduction of fever (Kanashiro et al. 2009; Malvar Ddo 
et al. 2014). Additionally, metamizole and MAA have been linked to prostaglandin-independent 
antipyretic effects but with still unknown mechanism (Malvar Ddo et al. 2014; Malvar Ddo et al. 
2011). Accordingly, metamizole has been shown to reduce fever induced by lipopolysaccharides, 
TNF-α, interleukin-1β, interleukin-6, and the release of corticotrophin releasing hormone from 
the hypothalamus (de Souza et al. 2002).  
1.1.3.4. Effect on platelet aggregation 
The effect of metamizole itself on platelet aggregation and thromboxane A2 synthesis as well as 
potential interactions with other platelet aggregating drugs has been studied intensively. Several 
studies showed effective inhibition of platelet aggregation and thromboxane A2 formation for 6 
hours in patients treated with metamizole (Graff et al. 2007; Papp et al. 2014). Various case-
control studies evaluated the risk of upper gastrointestinal bleedings and most of them reported a 
significantly increased risk associated with metamizole, which was generally lower than for 
nonsteroidal anti-inflammatory drugs (NSAIDs) but higher compared to paracetamol (Andrade 
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et al. 2016). Accordingly, the mortality associated with gastrointestinal complications related to 
metamizole was lower than for NSAIDs (Andrade et al. 1998). However, metamizole reduced the 
inhibitory effect of low-dose acetyl salicylic acid on platelet aggregation, potentially by a 
competitive interaction between the two drugs (Papp et al. 2014). This unwanted effect of 
metamizole on acetyl salicylic acid platelet aggregation inhibition can be circumvented by 
metamizole intake after acetyl salicylic acid (Polzin et al. 2015). Furthermore, arachidonic acid-
induced platelet aggregation was inhibited by metamizole, maybe by exhausting the arachidonic 
acid pool due to metabolite formation of metamizole with arachidonic acid (Pfrepper et al. 2019; 
Rogosch et al. 2012). 
1.1.4. Advantages of metamizole 
The proposed mechanisms of metamizole action might also explain the observed advantages of 
metamizole compared to NSAIDs. The described predominant COX-2 versus COX-1 inhibition 
would explain the good gastrointestinal tolerability of metamizole. The low risk for renal 
impairment might be based on the vascular smooth muscle relaxing effect improving renal blood 
circulation. Additionally, a meta-analysis of epidemiologic studies of serious adverse drug effects 
associated with various analgesics revealed that the absolute mortality risk associated with 
metamizole is over 20-fold lower than for NSAIDs (Andrade et al. 2016). Hence, metamizole 
represents a valuable reserve medication for patients with renal impairment, hypertension, 
increased bleeding risk, or intolerance for NSAIDs. Additionally, it has been shown that 
metamizole increases the analgesic effect of morphine also in presence of morphine tolerance 
(Hernandez-Delgadillo and Cruz 2004). Furthermore, the combination of metamizole and 
tramadol lead to synergistic analgesic effects, but only at dosages resulting in over 50% pain 
reduction (Poveda et al. 2003). Hence, dose reduction of opiates by combination with 
metamizole could reduce the risk for opiate adverse drug reactions (ADR) or addiction 
development. 
1.1.5. Toxicity beyond hematology 
Although high metamizole dosage is not a risk factor for metamizole-associated neutropenia, 
toxicity in other organs due to overdose has been reported. A review of metamizole overdoses 
reported predominantly mild gastrointestinal toxicity without any hematological ADR (Bentur 
and Cohen 2004). Accordingly, transient renal insufficiency and kidney injury has been described 
after metamizole overdose (Abu-Kishk et al. 2010; Berruti et al. 1998; Hassan et al. 2011; Peces 
and Pedrajas 2004; Stueber et al. 2017). The mechanism of kidney injury by metamizole might me 
similar as for NSAIDs by inhibition of the prostaglandin synthesis (Zapater et al. 2015). 
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Furthermore, it has been shown that the metamizole metabolite MAA is demethylated partly in the 
liver where also further metabolism might take place, whereby the formed and potentially toxic 
metabolites could cause liver injury. A study showed that metamizole was toxic for monocyte-
derived hepatocyte-like cells from patients who had experienced idiosyncratic drug-induced liver 
injury after metamizole treatment (Benesic et al. 2018). The mechanism of metamizole-induced 
liver toxicity is unknown and the incidence of metamizole-induced liver injury is very low 
(Andrade et al. 2016). 
1.2. Neutrophil granulocytes 
The cellular immune system consists of leukocytes, which can be subdivided into granulocytes 
(neutrophils, basophils, and eosinophils), lymphocytes (T-cells, B-cells, and natural killer cells), 
and monocytes. Granulocytes can be distinguished from the mononucleated lymphocytes and 
monocytes by their lobulated nucleus and the granules that have given the name to these cells 
(Borregaard and Cowland 1997). Based on the staining properties of their granules, granulocytes 
can be classified as eosinophils, which contain acidophilic granules, as basophils, which contain 
granules susceptible to basic dyes, and as neutrophils, whose granules react minimally to staining 
(Chan et al. 2010). Neutrophils represent the most abundant granulocytes and also the main part 
of leukocytes in the blood (Rosales 2018). 
Neutrophils originate from hematopoietic stem cells as initial precursors, which are slowly 
dividing and capable of self-renewal (Orkin and Zon 2008). Hematopoietic stem cells lose their 
self-renewing potential while developing into multipotent precursor cells that can give rise to all 
blood cell lineages (Gorgens et al. 2013). These multipotent precursors differentiate into 
granulocyte–monocyte progenitors in response to extracellular stimuli such as granulocyte-colony 
stimulating factor (G-CSF) and cytokines, and intracellular regulators, such as transcription 
factors. Subsequently, the cells commit to the neutrophil lineage by turning into myeloblasts 
(Lieschke et al. 1994; von Vietinghoff and Ley 2008). By transition from myeloblast to 
promyelocte stage, granulopoiesis is initiated and progresses onward the differentiation 
(Borregaard and Cowland 1997). Promyelocytes still have a round nucleus but are larger than 
myeloblasts and are characterized by the presence of azurophilic or primary granules. These 
peroxidase-positive granules are defined by their MPO content (Borregaard and Cowland 1997; 
Kjeldsen et al. 1993). Following the neutrophil maturation process the cells differentiate into 
myelocytes, which are characterized by appearance of specific or secondary peroxidase-negative 
granules, which are defined by their lactoferrin content (Borregaard and Cowland 1997; von 
Vietinghoff and Ley 2008). Next in the maturation sequence are metamyelocytes, which are 
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characterized by their kidney-shaped nucleus (Mora-Jensen et al. 2011; von Vietinghoff and Ley 
2008). Metamyelocytes differentiate into band neutrophils, characterized by their band-shaped 
nucleus and the appearance of gelatinase or tertiary granules, which are defined by their gelatinase 
content (Borregaard and Cowland 1997; Cowland and Borregaard 2016). Band neutrophils turn 
into fully mature neutrophils with a segmented nucleus and the presence of secretory vesicles, 
which are rich in various receptors (Cowland and Borregaard 2016). 
 
 
Figure 1 Neutrophil differentiation 
 
During the differentiation process, the cells are located in the bone marrow until the mature 
neutrophil stage at which the cells are able to enter the blood stream (Bainton et al. 1971). Once 
released into circulation, neutrophils exert their primary function in innate host defense by 
various methods. By contact and recognition of a pathogen, phagocytosis is induced and the 
pathogens are engulfed by the neutrophil plasma membrane into a newly formed vacuole, the 
phagosome. Next, the phagosome fuses with granules to form the phagolysosome (Murphy and 
Weaver 2017). At the same time, the neutrophil undergoes respiratory burst by which the 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex assembles at the 
plasma or phagosomal membrane due to neutrophil activation (Nauseef 2004). NADPH oxidase 
converts oxygen to superoxide, which is further converted to the MPO substrate hydrogen 
peroxide by superoxide dismutases (SOD). MPO is a heme-containing enzyme located in the 
azurophilic granules of neutrophils (Fiedler et al. 2000; Oren and Taylor 1995). MPO released 
from granules after fusion with the phagosome uses hydrogen peroxide formed by NADPH 
oxidase to catalyze the production of the antimicrobial hypochlorous acid (Bardoel et al. 2014). 
Hence, the phagolysosome contains hydrogen peroxide, hypochlorous acid and degrading 
enzymes to destroy the ingested pathogens (Rosales 2018). Neutrophils can also fuse their 
granules with the plasma membrane to release their content and attack surrounding pathogens. 
Further, neutrophils may produce extracellular traps (NET) consisting of DNA fibers and 
proteins from the granules to fend invading microorganisms even after neutrophil cell death 
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(Bardoel et al. 2014; Rosales 2018). In contrast to lymphocytes and monocytes, neutrophils have 
a short lifespan of less than 24 hours in circulation, for which reason any disturbance in 
myelopoiesis shortly ends in a lack of circulating neutrophils and risk of neutropenia (McCracken 
and Allen 2014). 
1.3. Metamizole-associated neutropenia 
Despite the good efficacy and gastrointestinal tolerability, metamizole has been banned in several 
countries (Sweden, USA, India) due to reports of metamizole-associated neutropenia (Blaser et al. 
2015; Hedenmalm and Spigset 2002). Neutropenia is a decrease of circulating neutrophils below 
1.5 x 109 cells/L and therefore represents a severe impairment of the innate immune system.  
A decrease of the neutrophil count to less than 1.5 x 109/L (neutropenia), or less than 
0.5 x 109/L (severe neutropenia or agranulocytosis) increases the susceptibility of the organism to 
infections. The first clinical manifestations often are inflammatory mucosal lesions, sore throat 
with or without fever, which is followed by infections such as tonsillitis or pneumonia and in 
severe cases sepsis and/or death. Depending on severity of the neutropenia and accompanying 
infections, patients are treated with G-CSF and antibiotics and by removal of all potentially 
neutropenia-causing drugs. Despite any treatment efforts, neutropenia is a serious disease with a 
fatality rate of approximately 5% (Andres and Maloisel 2008). 
The mechanisms of metamizole-induced neutropenia are still under debate and there are no 
effective strategies to predict in whom it is likely to occur, nor to prevent this severe ADR 
(Andres and Maloisel 2008; Garbe 2007). The chemical structure of metamizole is closely related 
to aminopyrine, a drug which was withdrawn from the market after it had been associated with 
agranulocytosis in the 1930s (Huguley 1964). Investigations of the underlying mechanism of 
aminopyrine-induced agranulocytosis showed leucocyte agglutination with serum of previously 
sensitized patients in the presence of aminopyrine. Additionally, an observed increase in 
symptom-severity upon re-exposure as well as fever and rash in some patients suggest an 
immunologic mechanism of metamizole-induced neutropenia (Moeschlin 1955; Moeschlin and 
Wagner 1952). On the other hand, certain characteristics such as the rapid onset within a day 
after the first few doses in some patients without known previous exposure and the observation 
of bi- and pancytopenia are more compatible with direct toxicity of metamizole or its metabolites 
on circulating cells and/or their precursors in the bone marrow. This theory is in agreement with 
descriptions of bone marrow smears in patients with metamizole-associated agranulocytosis, 
showing a stop at the promyelocyte stage in the maturation of granulocytes (Kummer et al. 2006). 
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This observation indicates that the causing agent acts within the bone marrow by destroying 
immature and therefore potentially more sensitive cells. Hence, peripheral destruction can be 
excluded as the major mechanism, since in that case an increased proliferation of the entire cell 
lineage would be expected due to a feedback mechanism. Additionally, the unique neutrophil 
characteristic to form highly reactive compounds such as hydrogen peroxide and hypochlorous 
acid might contribute to the formation of potentially cytotoxic metamizole metabolites in the 
bone marrow. 
Besides external influences, the patient’s genetic predisposition can have a major impact on the 
risk to develop an ADR. Hence, pharmacogenetics testing for markers of ADR risk is used in the 
USA for several drugs (e.g. carbamazepine, abacavir, azathioprine) to decrease the ADRs (Lesko 
and Zineh 2010). For various ADRs (e.g. drug-induced liver injury, Steven-Johnson 
syndrome/toxic epidermal necrolysis) strong associations with variants in the human leukocyte 
antigen (HLA) region have been described (Daly et al. 2009; Hung et al. 2006; Mallal et al. 2002). 
The identification of genetic variants associated with increased ADR risk might help to prevent 
life-threatening ADRs and could also lead to a better understanding of the underlying 
mechanisms of these reactions. Since patients experiencing metamizole-associated neutropenia 
represent a very heterogeneous population with no clinical or demographic predictive factors, a 
genetic basis for metamizole-associated neutropenia is likely. 
1.4. Risk factors 
There are currently no predictable risk factors for metamizole-associated neutropenia. This ADR 
has been observed in infants up to elderly without any dose-dependency, which raises the urge to 
find predictive factors to minimize the number of affected patients. With this aim, several studies 
have been performed, reporting a higher rate of metamizole-associated neutropenia among 
elderly people and women (Blaser et al. 2015; Maj and Lis 2002). This might be exposure-related 
due to the higher analgesic use among elderly and the more frequent physician visits and 
therefore higher prescription rate for women. No association has been described for dosage or 
treatment duration and neutropenia occurrence (Andersohn et al. 2007; Andrade et al. 2016; 
Blaser et al. 2015).  
Co-medication with myelotoxic or immunosuppressive drugs might potentiate the risk of 
neutropenia during metamizole treatment. Treatment with methotrexate combined with 
metamizole has been shown to be a risk factor for fatal neutropenia (Blaser et al. 2015; 
Stammschulte et al. 2015). Also non-myelotoxic and non-immunosuppressive drugs can elicit 
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neutropenia and might increase the risk of metamizole-associated neutropenia when combined 
(Andersohn et al. 2007). There are no reports about reduced metamizole metabolism and 
therefore increased metamizole plasma levels due to other drugs. However, since metamizole-
associated neutropenia is not dose-dependent, reduced metamizole clearance can be excluded as 
potential risk factor.   
Comorbidities affecting the neutrophil count might amplify possible metamizole-induced 
neutrophil loss. Especially immune depriving illnesses but also viral, bacterial, or fungal infections 
are known to reduce the neutrophil count in the circulation and bone marrow (Boxer and Dale 
2002; Celkan and Koç 2015; Galani and Andreakos 2015). It has been shown for HIV and its 
equivalent in rhesus macaques, SIV, to induce neutrophil apoptosis leading to neutropenia 
(Elbim et al. 2009; Salmen et al. 2007). Accordingly, influenza A virus infection accelerates 
neutrophil apoptosis and the rate and extent of apoptosis was enhanced by an additional bacterial 
infection (Colamussi et al. 1999). Infected cells may be more sensitive to drugs and metabolites 
than healthy cells. This theory is supported by the observation that peripheral blood mononuclear 
cells infected with HIV or SF-162 virus were more susceptible to sulfamethoxazole 
hydroxylamine metabolite toxicity (Levy 1997). This observation is in line with the observation of 
an increased prevalence of hepatitis C infections in patients who developed metamizole-
associated leukopenia (Blaser et al. 2017).  
1.5. Heme metabolism 
It has been shown that the metamizole metabolites MAA and AA can form stable complexes 
with heme and that MAA is able to reduce Fe3+ to Fe2+ (Pierre et al. 2007). Accordingly, in the 
subsequent original research, the interaction of MAA and the hemoglobin degradation product 
hemin is of central interest, for which reason a short overview about cellular heme metabolism 
will complete this introduction.  
When old erythrocytes are removed from the circulation, the contained hemoglobin is degraded 
and the iron is recycled, avoiding any free heme generation (Chung et al. 2012; Kumar and 
Bandyopadhyay 2005). Hemoglobin degradation mostly takes place in spleen, liver, bone marrow, 
and macrophages and the accruing heme or its oxidized form hemin are further degraded by 
heme-oxygenase to iron, biliverdin, and carbon monoxide (Pimstone et al. 1971; Wagner et al. 
1962). Released iron is either stored as ferritin-bond iron (Fe3+) or exported in reduced form 
(Fe2+) by the iron exporter protein ferroportin (Hentze et al. 2010). Exported iron is immediately 
bound by transferrin as ferric iron (Fe3+), which is taken up by cells over the transferrin receptor. 
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After binding of transferrin, the transferrin receptor complex is internalized through endocytosis 
(Schultz et al. 2010). In the emerging endosome, ferric iron and transferrin dissociate from the 
transferrin receptor due to the low pH and the iron is reduced to Fe2+ by STEAP 
metalloreductases. Ferrous iron (Fe2+) is then exported via the divalent metal transporter 1 to the 
cytosol, where it enters the cellular labile iron pool. A further iron acquisition pathway is apical 
absorption of dietary iron (Fe3+) after reduction by duodenal cytochrome b. Macrophages can 
also acquire heme-iron as heme-hemopexin complex or hemoglobin-haptoglobin complex or by 
phagocytosis of erythrocytes (Boretti et al. 2014; Hvidberg et al. 2005). Iron from the labile iron 
pool is utilized for direct incorporation into iron proteins or is transported into the mitochondrial 
intermembrane space by mitoferrin for synthesis of hemo-proteins or iron-sulfur cluster 
containing proteins (Chung et al. 2012; Hentze et al. 2010; Schultz et al. 2010). Heme is formed 
through an enzymatic cascade in the cytosol and the mitochondria (Hentze et al. 2010; Schultz et 
al. 2010). First, protoporphyrin IX precursor is synthesized in the mitochondrial matrix and 
exported to the cytosol, where it is converted to coproporphyrinogen III. Next, 
coproporphyrinogen III is transported into the mitochondrial intermembrane space and 
converted to protoporphyrin IX (Severance and Hamza 2009). Then iron is incorporated into 
protoporphyrin IX by ferrochelatase (Dailey et al. 2000; Lange et al. 1999). Unused iron can be 
either exported via ferroportin and loaded to transferrin or stored as ferritin-iron (Fe3+). The 
amount of iron present in the labile iron pool depends on iron uptake, utilization, storage, and 
export rates, which are tightly regulated to avoid iron excess or deficiency (Hentze et al. 2010). 
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2. RATIONALE AND MOTIVATION 
Although metamizole is an analgesic with several advantages compared to NSAIDs, it has been 
banned in several countries or been restricted to narrow indications as in Switzerland due to the 
rare occurrence of metamizole-associated neutropenia (UnitedNations 2005). Removing 
medications from the market due to severe ADRs is not an adequate solution regarding the need 
for effective alternative analgesics to NSAIDs. Patients intolerant to NSAIDs are left with fewer 
therapeutic options or need to switch to opiates, which may be inappropriate for the indication. 
A more preferable approach would be to elucidate the mechanisms of metamizole-associated 
neutropenia to identify potential risk factors. Hence, patients at risk could be monitored or 
excluded from metamizole treatment. The need for an alternative treatment option to NSAIDs 
has led to a continuous increase in metamizole prescriptions in recent years accompanied by a 
growing number of neutropenia reports (Blaser et al. 2015). The increasing use of metamizole in 
parallel with the uncertainty of its safety for the individual patient emphasizes the need to 
investigate the underlying mechanisms of this severe ADR. Despite the long history of 
metamizole use and awareness of its potential to induce neutropenia, the underlying mechanisms 
are still not understood. Immune-mediated mechanisms have been discussed as well as direct 
cytotoxic effects of metamizole or its metabolites, whereas the immune-mediated theory seems to 
be more accepted and widespread (Curtis 2014; Hamerschlak and Cavalcanti 2005; Uetrecht 
1996). The four main metamizole metabolites reach sufficiently high plasma and potentially also 
bone marrow concentrations to be hemotoxic (Blaser et al., unpublished data). Bone marrow 
biopsies of patients with metamizole-associated neutropenia consistently showed a stop at the 
promyelocyte differentiation stage in neutrophil maturation (Isik et al. 2014; Pfersdorff et al. 
2011). This observation indicates that potential cytotoxic metamizole metabolites affect the 
immature cells in the bone marrow and not mature cells in the circulation. Potentially cytotoxic 
metabolites would be expected to be formed either in the liver or in the neutrophils itself. It has 
been shown for the thienopyridine derivatives ticlopidin and clopidogrel to be metabolized by 
liver microsomes to metabolites, which were cytotoxic for myeloid progenitor cells. Additionally, 
MPO of neutrophils is able to convert ticlopidine and the main metabolite clopidogrel 
carboxylate to myelotoxic metabolites (Maseneni et al. 2012). 
The current work is part of a collaboration between pharmacology & toxicology, immunology, 
and genetics groups to investigate the underlying mechanisms of metamizole-associated 
neutropenia. This thesis covers the toxicological in vitro investigations of direct metamizole 
RATIONALE AND MOTIVATION 
24 
metabolite toxicity on neutrophils and neutrophil progenitor cells as well as clinical investigations 
composed of an observational case-control study. In the first part of this thesis, I will focus on 
the toxicological in vitro investigations and in the second part, I will present the results of the 
clinical data assessment of the observational case-control study. 
The in vitro investigations were based on previous experiments showing no cytotoxicity of 
metamizole and its main metabolites on mature neutrophils and the observation that bone 
marrow biopsies of neutropenia patients showed a maturation stop at the promyelocytic stage. 
Hence, I planned to investigate the cytotoxicity of metamizole and its main metabolites on the 
promyelocytic cell line HL60 and myeloid progenitor cells from umbilical cord blood in 
comparison with mature neutrophils. To form potentially cytotoxic secondary metabolites, I 
combined the metamizole metabolites with components of the neutrophil antioxidative system: 
MPO or horseradish peroxidase, hydrogen peroxide, and hypochloric acid. I further assessed 
potential formation of cytotoxic metabolites after combination of metamizole metabolites with 
various iron compounds found in neutrophils and blood. 
In a second in vitro project, I aimed to investigate the difference between HL60 cells and mature 
neutrophils leading to the observed higher resistance of mature cells. To assess potential cellular 
changes, I differentiated promyelocytic HL60 cells into mature neutrophils and investigated the 
change in protein expression of heme-metabolizing enzymes and enzymes involved in the first 
line antioxidative defense as well as the cellular glutathione pool. 
The observational case-control study was based on a previous retrospective analysis of the 
hematological safety of metamizole using reports from the WHO Global Database and the Swiss 
Pharmacovigilance Database (Blaser et al. 2015). The main risk factors for fatal outcome found in 
this analysis were female gender, higher age, and co-medication with methotrexate, an 
immunosuppressive drug known to cause neutropenia. Interestingly, about a third of all 
neutropenia cases occurred within a latency time of less than 7 days, questioning the concept of 
an immunological reaction as underlying mechanism. In contrast to this previous retrospective 
analysis, all included patients were interviewed personally to get a more complete image of the 
cases, enabling a more detailed risk analysis. Additionally, only cases without any myelotoxic or 
immunosuppressive co-medication were included. This allowed us to focus on the influence of 
daily co-medication, which has also been reported to influence the neutrophil count as well as 
other potentially involved risk factors (Andersohn et al. 2007). Case patients of this study were 
compared to controls, which are expected to be tolerant to metamizole. This was accomplished 
by inclusion of control patients, who had been under continuous metamizole treatment for at 
least 28 days without any hematological adverse events. According to previous studies, the risk 
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was very low that these patients would develop metamizole-associated neutropenia after this 
treatment period (Blaser et al. 2015). This study design enabled me to compare tolerant control 
patients, who received metamizole in an outpatient treatment setting, with a subgroup of all 
included neutropenia cases, who had developed neutropenia after metamizole treatment at home. 
Since these two groups had similar treatment circumstances, it was possible to analyze risk factors 
in a regression-based model.  
Since metamizole has been used as pain killer over almost 100 years and its potential to induce 
neutropenia has been described extensively but no mechanism has been identified so far, it is 
likely that several factors might influence the development of metamizole-associated neutropenia.  
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Legends to supplementary figures 
Figure S1 
Differentiation of HL60 cells. Promyelocytic HL60 cells were differentiated towards neutrophil 
granulocytes over 5 days and the success of differentiation was assessed morphologically 
and by expression of the surface marker CD66a. (A-D) Light microscopy. Cell preparations 
of HL60 cells at (A) day 0, (B) day 3, and (C) day 5 of differentiation. (D) freshly isolated 
neutrophil granulocytes. Cells were stained with Hemacolor® Rapid staining set (Merck, 
Darmstadt, Germany) for evaluation of cell morphology. Bars, 20 µm. (E) Expression of the 
surface marker CD66a on differentiating HL60 cells. (F) Assessment of cell viability during 
the differentiation process. Apoptosis and necrosis were assessed by staining with annexin V 
and propidium iodide, respectively. 
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Figure S2 
Metabolism of heme/hemin by heme oxygenase-1 (HO-1) and biliverdin reductase (BVR). 
HO-1 forms biliverdin by breaking the protoporphyrin ring of heme or hemin. The reaction 
consumes oxygen (O2) and releases an iron ion (Fe2+or Fe3+) and carbon monoxide (CO). 
HO-1 can be inhibited by zinc protoporphyrine (ZnPP). Biliverdin is reduced to bilirubin by 
BVR. BVR can be inhibited by montelukast. HO-1 and BVR both use electrons for their 
reactions, which are transferred from NADPH by cytochrome P450 reductase (CYPOR). 
CYPOR can be inhibited by the flavoprotein inhibitor diphenylene iodonium (DPI).  
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Figure S3 
Effect of heme metabolism enzyme inhibitors on the effect of MAA and hemin on 
undifferentiated and differentiated HL60 cells. Cells were treated with MAA and hemin for 24 
hours with or without inhibitors of heme metabolism enzymes and the effect on cell death by 
apoptosis or necrosis assessed. (A) Effect of heme oxygenase-1 inhibition by pretreatment 
with 10 µM zinc protoporphyrin (ZnPP) on undifferentiated HL60 cells. (B) Effect of HO-1 
inhibition by pretreatment with 10 µM ZnPP on HL60 cells differentiated for 4 days. (C) Effect 
of CYPOR inhibition by pretreatment with 20 µM diphenylene iodonium (DPI) on 
undifferentiated HL60 cells. (D) Effect of CYPOR inhibition by pretreatment with 20 µM DPI 
on HL60 cells differentiated for 4 days. Apoptosis and necrosis were assessed by staining 
with annexin V and propidium iodide, respectively. Doxorubicin (0.5 µM) was used as 
positive control. *p<0.05 vs. control incubations (Ctrl), +p<0.05 vs. incubations w/o enzyme 
inhibitor of the same treatment group. Ctrl: control. 
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Figure S4 
Western blot of heme degrading enzymes and antioxidative defense enzymes in 
differentiating HL60 cells and neutrophil granulocytes. HL60 cells were differentiated over 5 
days and neutrophil granulocytes isolated from whole blood. (A) Protein expression of 
cytochrome P450 reductase (CYPOR), heme oxygenase-1 (HO-1), biliverdin reductase 
(BVR), superoxide dismutase 1 (SOD1), and superoxide dismutase 2 (SOD2). GAPDH was 
used as loading control. (B) Protein expression of catalase (CAT), glutathione peroxidase 1 
(GPX1), and glutathione peroxidase 4 (GPX4). GAPDH was used as loading control, d0-d5: 
days of HL60 differentiation, N: neutrophil granulocytes. 
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Figure S5 
Mitochondrial copy number and protein expression of superoxide dismutase 2 (SOD2) 
relative to the mitochondrial copy number. SOD2 protein expression and the mitochondrial 
copy number were determined in differentiating HL60 cells and neutrophil granulocytes. (A) 
Mitochondrial copy number relative to undifferentiated HL60 cells. (B) SOD2 protein 
expression relative to mitochondrial copy number. +p<0.05 vs. undifferentiated HL60 cells, 
mtDNA: mitochondrial DNA. 
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5. DISCUSSION 
In several assays elucidating the cytotoxic potential of metamizole and its metabolites, the main 
metabolite MAA was showing unexpected characteristics. While no cytotoxicity was detectable at 
pharmacological concentrations, MAA improved the viability of the treated cells compared to 
untreated cells. Especially under stress-inducing conditions, when cells are treated with hydrogen 
peroxide for example, MAA increased the cell viability by its radical scavenging characteristic. 
This circumstance first hampered the process to find a cytotoxic mechanism of metamizole-
associated neutropenia, but then also revealed a potential mechanism, how MAA could elicit 
cytotoxicity. While detoxifying radicals by donating protons or adsorbing electrons, radical 
scavengers themselves form intermediate radicals, which normally are immediately further 
degraded to unreactive compounds (Fujii et al. 2011; Valko et al. 2006). But in presence of a 
highly oxidative compound, radical scavengers cannot regenerate their antioxidative properties 
and turn themselves into reactive electrophilic intermediates (Valko et al. 2006). I have shown 
that this is the case for MAA when combined with hemin. Heme is part of hemoglobin and 
myoglobin where it carries oxygen as well as part of several enzymes, which use heme as active 
site to perform electron-transfer, oxygen delivery, catalysis, and signaling (Kumar and 
Bandyopadhyay 2005; Yan et al. 2017). In my studies, heme or hemin did not react with MAA 
when they were bound inside of hemoglobin or methemoglobin, respectively. The globin chains 
seemed to shield the iron ions strong enough so that MAA was not able to get in contact with the 
iron to react. Heme or hemin can be released in case of hemoglobin or methemoglobin 
degradation. Heme and hemin normally do not occur freely since they damage lipids, proteins, 
and DNA through reactive oxygen species (ROS) generation (Wagener et al. 2001). Free heme is 
avoided by immediate further degradation by heme-oxygenase (Chung et al. 2012; Kumar and 
Bandyopadhyay 2005). But in case of excess erythrocyte degradation during hemolysis, the heme 
degrading system is overcharged and hemoglobin undergoes accelerated oxidation and oxidative 
changes leading to heme loss (Buehler et al. 2011). Free heme is readily oxidized to hemin and is 
able to enter neutrophils and their precursors, where it can react with MAA to form reactive 
MAA intermediates. Since heme is also often contained in enzymes, most cells, including 
neutrophils, produce heme to incorporate it into their hemoproteins (Hentze et al. 2010). Hence, 
heme is naturally present in neutrophils and neutrophil precursor cells and could in case of 
impaired heme metabolism inside the cells accumulate and potentially react with MAA, thereby 
forming reactive intermediates leading to neutropenia. The iron ion of hemin is bound to four 
pyrrole nitrogens resulting in an open axial coordination site that can bind oxygen (Ryu et al. 
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2016). Its reversible redox characteristics enable rapid electron transfer to and from these iron 
ions (Que Jr and Tolman 2008). Hence, one hemin molecule can oxidize several other 
compounds, which reflects its high oxidative capacity. In case of cytotoxicity assays described 
within this thesis, eight times less hemin than MAA was enough to produce sufficient MAA 
electrophilic intermediates to induce apoptosis in HL60 cells. Hemin itself showed a 
concentration dependent cytotoxicity, which was strongly amplified in combination with MAA. 
Then again, MAA-hemin cytotoxicity showed different characteristics than hemin cytotoxicity, 
especially in differentiating HL60 cells. Hemin cytotoxicity was detectable up to higher 
differentiation stages than MAA-hemin cytotoxicity, indicating a different mechanism leading to 
apoptosis. Especially the observed marginally mitochondrial toxicity could all be contributed to 
hemin, which was potentially due to ROS production (Kumar and Bandyopadhyay 2005). The 
different maturation stages of cells investigated within this thesis showed striking differences 
regarding their resistance not only against MAA-hemin, but also when treated with hemin alone 
or the oxidant hydrogen peroxide. Compared to other immune cells, neutrophils have a very 
short life-span in the circulation (Boxer and Dale 2002). Therefore, neutrophils do not need to 
maintain higher cellular functions, which enable these cells to invest everything into defense 
systems instead of survival mechanisms. In contrast, immature neutrophils have more days of 
existence ahead and are still developing their cellular properties, which need more energy and 
resources from outside. This renders immature cells more susceptible for external and internal 
damaging influences. During myeloid differentiation from myeloblasts to mature neutrophils, 
which takes around 10 to 16 days in vivo, the cells undergo drastic morphologic, metabolic and 
enzymatic changes (Boxer and Dale 2002; Boyunaga et al. 2010; Jacque et al. 2015). In view of 
the final purpose of neutrophils, the protection of the organism against invading pathogens by 
production of highly oxidative compounds, neutrophils need a resilient system to protect 
themselves from their own weapons. Hence, neutrophils possess a strong antioxidative defense 
system able to degrade high concentrations of hydrogen peroxide (Bardoel et al. 2014; 
Splettstoesser and Schuff-Werner 2002). In the second in vitro study of this thesis, I have shown 
that the antioxidative defense system is significantly less pronounced in promyelocytic HL60 
cells. This difference explains the observed susceptibility of HL60 cells to MAA-hemin as well as 
to hydrogen peroxide, which was not detectable in mature neutrophils. Besides the antioxidative 
defense, also the heme-metabolizing capacity increases during neutrophil maturation. Hence, the 
cells are able to degrade hemin faster and thus to interrupt potential radical formation with MAA. 
This is of importance since, as mentioned above; one hemin molecule can react with several 
MAA molecules. Thus, fewer MAA radicals can be formed and damage the cells. It cannot be 
distinguished, whether the antioxidative defense or the heme-metabolizing capacity is more 
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important in the observed resistance of higher differentiated cells. It is also likely that both 
mechanisms synergistically are responsible for the changed susceptibility.  
During infections, immune cells are recruited and activated. This leads to metabolic changes 
within the cells that potentially increase their susceptibility to MAA-hemin. Neutropenia patients 
of our cohort often also showed decreased lymphocyte counts. This has also been described for 
other drug-induced neutropenia (Tesfa et al. 2009), supporting the theory that metabolic changes 
and/or increased hemolysis due to infections could have an impact on cellular susceptibility to 
MAA-hemin. In contrast to mature neutrophils, mature lymphocytes predominantly use oxidative 
phosphorylation for their ATP generation (Kramer et al. 2014). During infections, when 
lymphocytes are activated, they undergo a metabolic switch from oxidative phosphorylation to 
glycolysis (Pearce and Pearce 2013). This might turn lymphocytes more susceptible to 
metamizole toxicity. Mature neutrophils only rely on glycolysis for ATP generation, but in 
contrast to lymphocytes, they possess a stronger antioxidative capacity due to their own ROS 
production (Chacko et al. 2013; Kramer et al. 2014). Immature neutrophils also predominantly 
generate ATP by glycolysis but have a weaker antioxidative defense and hemin-metabolism 
capacity (Boyunaga et al. 2010). Hence, MAA-hemin cytotoxicity might affect cellular glycolysis 
leading to impaired ATP generation followed by cell death. In case there are sufficient defense 
mechanisms to detoxify formed MAA radicals, the cellular ATP generation will not be affected, 
and cell viability is maintained. Moreover, infections can lead to increased hemolysis (Berkowitz 
1991), making more hemin available to react with MAA. Hemin can be taken up into the 
neutrophil precursor cells or, as mentioned before, be produced within the cells themselves. 
Furthermore, acute infections stimulate granulopoiesis within the bone marrow, thereby 
increasing the number of neutrophils in the circulation to limit the infection and to replenish the 
depleted progenitor populations in the bone marrow (Glatman Zaretsky et al. 2014). Thus, bone 
marrow and progenitor cell metabolism are increased, which could lead to higher susceptibility to 
reactive MAA intermediates. Since hemin, but not hydrogen peroxide, was able to form enough 
reactive MAA intermediates in vitro, it is possible that a constant source of oxidants is needed. 
This could be hemin, which can react with several MAA molecules, or continuously produced 
oxidizing free radicals. During oxidative burst due to inflammatory processes, immune cells 
produce superoxide anions and nitric oxide, which may react to even more reactive peroxynitrite 
anions (Carr et al. 2000). Peroxinitrite can cause DNA fragmentation and lipid peroxidation and 
if continuously produced, peroxinitirite potentially could oxidize MAA to electrophilic 
intermediates. Hence, the combination of continuously produced oxidants during infection and 
impaired antioxidative defense in neutropenia patients could be the crucial difference compared 
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to tolerant control patients who also had infections, but a fully functional antioxidative defense 
system. 
The observation that lymphocytes are also often affected by metamizole in neutropenia patients 
points to a toxicological mechanism in vivo. Additionally, the often mentioned potential risk 
factors for immune-mediated neutropenia, history of positive drug allergy or autoimmune 
diseases (Andres et al. 2011), were less frequent among neutropenia patients compared to tolerant 
control patients of our cohort. This does not exclude an immune-mediated mechanism of 
metamizole-associated neutropenia but makes an immunological predisposition less likely. A 
systematic analysis of the peripheral blood in neutropenia patients and tolerant controls from our 
cohort did not reveal any activation of the adaptive immune system (Dina et al. 2019, under 
review). These findings support a cytotoxic mechanism of metamizole-associated neutropenia. 
Furthermore, immune reactions to drugs need about 2 weeks to develop (Schonhofer et al. 2003), 
but many neutropenia cases elicited neutropenia after only a few days of metamizole treatment 
without previous contact to the drug. 
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6. CONCLUSION 
The different susceptibility of immature and mature neutrophils to MAA-hemin cytotoxicity 
might point to a possible mechanism of metamizole-associated neutropenia observed in vivo. 
MAA can be transformed to an electrophilic intermediate in presence of highly oxidative 
compounds such as hemin. Thus, increased radical formation or decreased radical detoxification 
capacity might be crucial to whether a patient under metamizole treatment elicits neutropenia or 
not. The main result of the clinical data assessment showed that infections were twice as frequent 
among neutropenia patients compared to tolerant control patients. These infections potentially 
increased the susceptibility of neutrophil precursor cells to MAA radicals. Thus, highly oxidative 
compounds, which are generated continuously during infections, could form more electrophilic 
MAA intermediates than MAA is able to scavenge. However, the development of metamizole-
associated neutropenia seems to require more than an infection during metamizole treatment, 
since also tolerant control patients had infections without any hematological adverse events. 
Cellular predisposition consisting of either low antioxidative capacity, poor heme metabolism, 
increased free heme generation, or increased production of other highly oxidative compounds 
may render cells more susceptible to MAA toxicity. Hence, addition of infections to already 
susceptible cells may facilitate or accelerate the development of neutropenia. 
In contrast to general view, the results presented in this thesis favor a cytotoxic mechanism of 
metamizole-associated neutropenia. In vitro data illustrated a pathway, by which MAA can form a 
reactive electrophile intermediate that induces apoptosis in promyelocytic HL60 cells. Clinical 
data revealed no association between autoimmune diseases or drug-allergy history and 
neutropenia development, suggesting no involvement of the adaptive immune system. 
Additionally, high frequency of infections among neutropenia patients before neutropenia 
diagnosis points to an involvement of an aberrant cellular environment. This could be altered cell 
metabolism, increased heme concentration due to hemolysis or impaired heme metabolism, 
increased ROS production, or a too weak antioxidative defense system. 
The aim of this thesis was to investigate the mechanism of metamizole-associated neutropenia to 
identify potential risk factors for patients. The clinical study data assessment showed a smaller 
impact of non-myelotoxic and non-immunosuppressive co-medication and the immune system 
than assumed. Nevertheless, acute infections seem to increase the risk to develop metamizole-
associated neutropenia and may require additional surveillance in patients under metamizole 
treatment. Additionally, more awareness is needed concerning adequate patient information 
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including first signs of neutropenia and how to react in case of suspected neutropenia to prevent 
future fatal cases by early diagnosis and treatment.  
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7. OUTLOOK 
Some further in vitro investigations regarding the mechanism by which reactive MAA 
intermediates are damaging neutrophil precursor cells have already been pursued. Since MAA-
hemin leads to a drop in ATP in HL60 cells, the next step was to investigate a potential 
impairment of cellular energy generation by MAA radicals. First assays showed that when HL60 
cells are forced to use only oxidative phosphorylation for ATP generation, cytotoxicity of MAA-
hemin was significantly reduced. This suggests that mitochondria are not involved in the 
observed cytotoxicity. In a next step, the impact of MAA-hemin on cellular glycolysis was 
investigated. Since neutrophils and also neutrophil precursor cells rely predominantly on 
glycolysis for ATP generation, any damage to this system would strongly impair the cellular 
energy metabolism. The assessment of the cellular energy metabolism showed that MAA-hemin 
compromises glycolysis, leading to the observed drop in ATP, which may also be the cause of 
apoptosis.  
The genetic study of the collaborating genetics group investigating potential predispositions for 
metamizole-associated neutropenia is still ongoing. So far, no significant genetic differences 
between neutropenia cases and controls have been detected. Since the sample size is relatively 
small, significant outcomes would need a larger control group. It is therefore planned to include 
more healthy control subjects from a genetic databank in Bern to enlarge the control group. 
Moreover, there is the possibility to receive genetic data from metamizole-associated neutropenia 
cases from other countries. This would make it possible to verify so far not significant but 
promising genetic variants in other neutropenia cohorts.  
The main finding of the clinical data assessment of the case-control study was the higher 
frequency of infections among neutropenia cases compared to controls. To verify the impact of 
infection on the risk to develop metamizole-associated neutropenia, a higher number of study 
participants, which are compared to age-matched controls, is required. Therefore, control 
patients without inclusion criteria of a minimal metamizole intake period should be included, 
since long-term analgesic treatment is more common at higher age.  
For subsequent in vitro investigations, cellular changes during infections and the involved enzymes 
may be assessed. These cellular changes would normally not lead to neutropenia, but in 
combination with possibly impaired antioxidative defense or low heme-metabolizing capacity 
could serve as the triggering factor for neutropenia development. Thus, potential in vitro findings 
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could be verified in an animal model with humanized immune cells. Mouse models with 
humanized neutrophils as well as lymphocytes have been successfully generated by several groups 
for investigations of the immune system (Coughlan et al. 2012; Evering and Tsuji 2018). Hence, 
the involvement of the previously identified enzymes in vitro could be investigated by knock-
down of these enzymes and MAA treatment in presence of an infection. 
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